Left Menu
Development News Edition

Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms

Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized patients with mild-to-moderate COVID-19, the disease caused by the novel coronavirus. When asked whether the company would apply for emergency use authorization from the U.S. Food and Drug Administration, the company said it plans to "rapidly" discuss the early trial results with regulatory agencies, including the U.S. Food and Drug Administration.

Reuters | Washington DC | Updated: 30-09-2020 01:41 IST | Created: 30-09-2020 01:31 IST
Regeneron says its COVID-19 treatment reduces viral levels, improves symptoms
Representative image Image Credit: ANI

Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized patients with mild-to-moderate COVID-19, the disease caused by the novel coronavirus.

When asked whether the company would apply for emergency use authorization from the U.S. Food and Drug Administration, the company said it plans to "rapidly" discuss the early trial results with regulatory agencies, including the U.S. Food and Drug Administration. Results for the first 275 trial patients showed the greatest effect in patients who had not mounted their own immune response prior to treatment, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response, Regeneron said.

REGN-COV2 is part of a class of biotech therapies known as monoclonal antibodies. Several companies are using the technology to manufacture copies of the body's own antibodies to the new coronavirus. Regeneron believes its dual-antibody formula will limit the ability of the virus' to escape detection. The study tested two different doses of REGN-COV2 in two patient populations: those who mounted an effective immune response on their own (seropositive), and those whose immune response was not yet adequate (seronegative).

For patients given a placebo, the seropositive group had a median time to alleviation of symptoms of 7 days, compared to 13 days for seronegative patients. Regeneron said REGN-COV2 rapidly reduced viral load through day 7 in seronegative patients. In addition, patients with higher baseline viral levels had correspondingly greater reductions in viral load with REGN-COV2, which is given by intravenous infusion.

For seronegative patients, median time to symptom alleviation was 13 days for the placebo group, 8 days for the high-dose group, and 6 days for the low-dose group. Serious adverse side effects occurred in two placebo patients, one low-dose patient and no high-dose patients. There were no deaths in the trial.

REGN-COV2 is also being studied for the treatment of hospitalized patients, and for prevention of infection in people who have been exposed to COVID-19 patients.


TRENDING

OPINION / BLOG / INTERVIEW

New farm bills in India: Focusing on farms or farmers?

... ...

Kenya’s COVID-19 response: Chaos amid lack of information

Confusing numbers and scanty information on how effective curfews and lockdowns have been in breaking transmission have amplified coordination and planning challenges in Kenyas response to COVID-19. Without accurate data, it is impossible t...

Farkhad Akhmedov: Calculating the price of impunity from the law

In insistences such as the battle over the Luna, Akhmedov has resorted to extreme legal machinations to subvert the High Courts decision and keep his assets from being seized. ...

Guinea’s elections hearken back to the autocracy and violence of its past

... ...

Videos

Latest News

Unrest flares again in Lagos after civilians fired on in anti-police demonstrations

Nigerias biggest city Lagos and several states were under curfews on Wednesday as unrest rooted in anti-police protests broke out again following a day of violence, including the shooting of civilians by security forces.Fires burned across ...

UP police secures nearly 11k undertakings from potential troublemakers against women

The Anti-Romeo Squads of Uttar Pradesh police have been able to secure nearly 11,000 undertakings from potential trouble makers against women and girls to desist from committing any mischief against them, a government official said on Wedne...

AstraZeneca COVID-19 vaccine trial volunteer has died, Brazil health authority says

Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University has died, stating it had received data from an investigation into the matter. Th...

French prosecutor says students helped killer find teacher

The 18-year-old suspected killer of a French teacher who had shown caricatures of the Prophet in class paid students to help him identify the victim, Frances terrorism prosecutor said on Wednesday. Prosecutor Jean-Francois Ricard said a 14-...

Give Feedback